Pharma Journalist -

Merck, known as MSD outside the United States and Canada, announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and…
Read More...

High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies…
Read More...

RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical…
Read More...

Conference Chair shares his views on the HPAPI industry for the upcoming Highly Potent Active Pharmaceutical Ingredients conference SMi Group’s Highly Potent Active Pharmaceutical…
Read More...

OSE Immunotherapeutics SA and Servier announced the execution of an amendment to the two-step global licensing option agreement for exclusive global rights to interleukin-7 receptor…
Read More...

Regeneron Pharmaceuticals, Inc. announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before…
Read More...

Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous…
Read More...

Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of…
Read More...

Aurinia Pharmaceuticals Inc. announced that the Company has initiated a Rolling Submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for…
Read More...

Beijing Tide Pharmaceutical Co., Ltd. (Tide), a subsidiary of Sino Biopharmaceutical Limited, and Insilico Medicine, an artificial intelligence company developing end-to-end drug…
Read More...